Clinical trials: Target Organ Damage
Hypertension, Hypertension (HTN)
Common Carotid Artery-Renal Artery-Femoral Artery Survey for Hypertension
To evaluate both sides of the common carotid artery, renal artery, and femoral artery in Hypertension patient that cause of systemic arterial hypertension and/or the effects of target organ damage, both structural and functional…
- Conditions
- Hypertension, Hypertension (HTN), Artery Disease, Target Organ Damage
- Trial name
- CRF Survey (NCT07760623)
- Testing
- Diameter measurement, Velocity
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- DejthidaNathaphong
Hypertension, Target Organ Damage
GlycOxiTOD: Multimodal Vascular and Target-Organ Damage Registry
The goal of the GlycOxiTOD observational registry is to improve the early detection and characterization of vascular and other target-organ damage in adults at increased cardiovascular risk.
- Conditions
- Hypertension, Target Organ Damage, Heart Disease Risk Factors, Vascular Stiffness
- Trial name
- GlycOxiTOD (NCT06325800)
- Testing
- Multimodal Cardiovascular Phenotyping
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Complejo Hospitalario Universitario de Santiago
Blood Pressure, Cardiovascular Risk Factor
Non-Invasive Aortic Ambulatory Blood Pressure Monitoring for The Detection of Target Organ Damage in The Chinese Population
This study is a sub-investigation of SAFAR study. Consecutive patients with established hypertension (treated or untreated with antihypertensive drugs) or with suspected hypertension are recruited and their 24-hour brachial and…
- Conditions
- Blood Pressure, Cardiovascular Risk Factor, Target Organ Damage, Cardiovascular Events
- Trial name
- SAFAR-China (NCT03154203)
- Testing
- No intervention in this study
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Shanghai 10th People's Hospital
Target Organs Damage, Hypertensive
Evaluation of Target Organs Damage in Hypertensive Patients
Evaluation of target organs damage in hypertensive patients with no known cardiovascular (CV) or renal disease, stratified according to level of blood pressure control
- Conditions
- Target Organs Damage, Hypertensive, no Known Cardiovascular, no Known Renal Disease
- Trial name
- PreVENT-A GP (NCT01055353)
- Where
- 905 sites in France
- Volunteers
- 1,857 people
- Sponsor
- AstraZeneca